Target intelligence / Profile preview

High mobility group AT-hook 1 pseudogene 7 (HMGA1P7)

Target
HMGA1P7
Molecular classification
Pseudogene, Long non-coding RNA (lncRNA)
01

Overview

HMGA1P7 is a processed pseudogene and lncRNA, located on chromosome 6q23.2, that shares high sequence homology with the parental HMGA1 gene but cannot be translated into functional protein due to a mutation in the initiator methionine codon. Instead, HMGA1P7 regulates gene expression post-transcriptionally by competing endogenous RNA (ceRNA) activity: it sequesters microRNAs that target the HMGA1 gene and other cancer-related genes such as HMGA2, EZH2, and VEGF, thereby upregulating their expression. Overexpression of HMGA1P7 has been associated with increased cellular proliferation, decreased apoptosis, enhanced migration and invasion, and higher tumor aggressiveness in both cellular and animal models. In transgenic mice, overexpression causes hematological neoplasia, notably diffuse large B-cell lymphoma, providing functional evidence of its oncogenic potential in vivo. As such, HMGA1P7 is an important regulator in cancer biology, despite not being a typical therapeutic target or druggable protein.

Other names
HMGA1-pseudogene 7HMGA1P7 lncRNA
02

Mechanism of action

Not applicable. No agents are known to act directly on HMGA1P7. Its biological effect is mediated by acting as a microRNA "sponge," sequestering microRNAs that would otherwise repress key oncogenes.

03

Biological functions

Competing endogenous RNA (ceRNA) activity / microRNA decoyRegulation of gene expression (specifically of HMGA1, HMGA2, EZH2, VEGF, and others)Modulation of cell proliferation, cell cycle progression, and apoptosis via indirect control of gene expression
04

Disease associations

Cancer (Documented in B cell lymphomas, anaplastic thyroid carcinomas, and other types of aggressive tumor)Hematological neoplasia (e.g., diffuse large B-cell lymphoma)
05

Safety considerations

Not directly applicable. However, any strategy modulating HMGA1P7 expression in vivo might present a risk of promoting oncogenesis, given the pseudogene's established role in facilitating tumor progression
06

Biomarkers

HMGA1P7 transcript levels may be explored as a biomarker of cancer aggressiveness or prognosis, particularly in lymphomas and aggressive thyroid cancers, based on studies correlating overexpression with advanced disease

Beyond the preview

Go deeper on High mobility group AT-hook 1 pseudogene 7 (HMGA1P7).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on High mobility group AT-hook 1 pseudogene 7 (HMGA1P7).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call